Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.
By Rachel Aldrich ,

NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report  are down 0.36% to $86.93 this morning as the company prepares to report 2016 second quarter earnings after the market close on Monday.

Analysts surveyed by Thomson Reuters are looking for earnings of $3.02 per share and revenue of $7.77 billion. For the 2015 second quarter, the company reported earnings of $3.25 per share and revenue of 8.2 billion.

Morgan Stanley analysts said the company will report disappointing earnings due to lower Hepatitis-C product sales, which the firm sees dropping on global pricing pressure and lower market share in Europe.

Gilead Sciences, a Foster City, CA-based biopharmaceutical company, holds core businesses in the Hepatitis-C and HIV markets.

Separately, TheStreet Ratings rated this stock as a "buy" with a ratings score of B.

The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. TheStreet Ratings feels its strengths outweigh the fact that the company has had sub par growth in net income.

You can view the full analysis from the report here: GILD

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

Loading ...